Shares of Biogen and other drugmakers researching Alzheimer’s disease soared early Wednesday after Japan’s Eisai Co. said its potential treatment appeared to slow the fatal disease in a late-stage study.
The drugmaker said early results showed that its treatment, lecanemab, reduced patient clinical decline by 27% when compared to a